Xiaowen Peng
Principal Scientist @ Montai Therapeutics
About
Passionate and experienced medicinal chemist and leader in small molecule drug discovery and early process development from project inception to clinical candidate selection. Key inventor of EDP-239, a HCV NS5A inhibitor that completed proof-of-concept clinical trial. Contributed to the discovery and development of EDP-514, a HBV core inhibitor completed phase 1 clinical trial, and EDP-235, a covalent SARS-CoV-2 3CL protease inhibitor in phase 2 clinical trial. Strong interest in chemical biology, especially with the design and synthesis of photo-affinity labeling tools for target identification.
United States
Watertown
Pharmaceuticals
Library Design, Parallel Synthesis, CRO Management, Nucleoside/tide synthesis, Prodrug Synthesis, Chemical Biology, Target Identification, Total Syntheis , Synthetic Organic Chemistry, 2D NMR Analysis, Process Route Scouting, Anti-Viral Drug Discovery, Computational Aided Drug Design, Anti-Viral, Covalent Inhibitor Design, CNS Drug Discovery, Project Management, Interdisciplinary Collaboration, Communication, Organic Synthesis
Experience
Principal Scientist
Montai Therapeutics
Cambridge, Massachusetts, United States
Medicinal Chemistry in immunology
Medicinal Chemistry Consulting
Novel prodrug design, CNS drug strategy design for improved brain penetration, CRO medicinal chemistry problem solving, Patent and publication Strategy consulting
Director, Medicinal Chemistry
Arkuda Therapeutics
200 Arsenal Yard Blvd, Suite 220, Watertown, MA 02472
* Led CRO teams on discovery and optimization of TRPML1 agonist. Successfully discovered a TRPML1 agonist scaffold with improved potency and high selectivity with established IP position. * Co-led CRO and collaborated with interdisciplinary teams on the discovery and optimization of next generation PGRN release enhancer for FTD based on potency, DMPK, PD and toxicology parameters. * Led the chemical biology effort on design and synthesis of photo-affinity labeling (PAL) tools for target identification. * Led the orthogonal chemical biology approach for target identification.
Principal Investigator
Enanta Pharmaceuticals
Watertown, Massachusetts, United States
Worked on the design and discovery of SARS-CoV-2 3CLPo and PLPro covalent protease inhibitors. Completed proof-of-concept of the new design of SARS-CoV-2 PLPro inhibitors by X-ray crystallography.
Principal Scientist
Enanta Pharmaceuticals
Watertown, Massachusetts, United States
1). Participate in the discovery of SARS-CoV-2 3CLpro oral inhibitors. Developed a key part of the process route for SARS-CoV-2 3CLpro clinical candidate EDP-235. 2). Discovery and process route development of HBV Class I (HAP) and Class II Core Protein Inhibitors.
Senior Scientist
Enanta Pharmaceuticals
Watertown, Massachusetts, United States
1). Discovery and Optimization of HCV NS5A Inhibitors. Key Inventor of HCV NS5A inhibitor Clinical Candidate EDP-239, which finished Proof-of-Concept clinical trial in a collaboration with Novartis. 2). Participate in collaboration with Novartis for the discovery of second generation HCV NS5A inhibitors.
Scientist
Enanta Pharmaceuticals
Participate in the discovery of HCV nucleoside/tide polymerase inhibitors and HCV NS5A inhibitors.
Postdoctoral Fellow
The Ohio State University
Columbus, Ohio, United States
Worked on the synthesis of C29-C51 segment (E/F rings) of spongistatin 1.
Research Associate
Neokimia Inc.
Sherbrooke, Quebec, Canada
Preparation of conformationally rigid macrocyclic peptide libraries for hit discovery and lead optimization.
Education
The Ohio State University
Chemistry
Completed the first asymmetric total synthesis of (+) and (-)-fomannosin.
The Ohio State University
Organic Chemistry
Completion of the synthesis of C29-C40 segment of pectenotoxin 2 (PTX2). Development of an alkoxide-directed hydrogenation.
Nankai University
Chemistry
Xiaowen Peng's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.